The upcoming AACR 2023 Annual Meeting will have a range of abstracts, including regular abstracts, clinical trials, and late-breaking abstracts. Among the abstracts being presented at the conference, we have listed a few potential abstracts, which we have listed in the below table. The table includes information about ongoing clinical trials for cancer drugs and devices, which various pharma companies are conducting in the high and mid stages of development. The agenda of this preview includes a quick glance at the top company-sponsored abstracts expected to present their much-awaited data readouts, while a few of them are all set to present their prospective trial designs.

  1. Data presentation by Key pharma players such as Roche in Hepatocellular Carcinoma, AstraZeneca and Daiichi in NSCLC, Merck in Biliary Tract Carcinoma, Chimerix in H3K27 mutant Glioma, Pfizer on BRAFV600 mutant melanoma and others players are highlighted in the below table:
S.NoDrug/DeviceCompanyTitlePatient segmentAbstract
1Atezolizumab + bevacizumabRocheIMbrave050: Phase III study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablationHCC at High Risk of Recurrence After Surgical Resection or Ablation (Adjuvant)CT003
2Durvalumab + platinum-based chemotherapyAstraZenecaAEGEAN: Phase III trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLCStages II and III NSCLC (Neoadjuvant/Adjuvant)CT005
3Pembrolizumab + gemcitabine + cisplatinMerck & CoKEYNOTE-966: Pembrolizumab in combination with gemcitabine and cisplatin for advanced biliary tract cancer a Phase III studyAdvanced and/or Unresectable Biliary Tract Carcinoma (1L)CT008
4Dordaviprone (ONC201)ChimerixACTION: Phase III study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse gliomaH3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy (1L)CT060
5Optune + Radiation therapy + Temozolomide (*Optune is a device)NovoCureTRIDENT: Phase III study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastomaGlioblastoma (1L)CT061
6Gedatolisib + fulvestrant ± palbociclibCelcuityVIKTORIA-1: Phase III study of gedatolisib + fulvestrant  ± palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitorPatients With HR+/HER2- Advanced Breast Cancer  (2L)CT063
7GLSI-100Greenwich LifeSciencesFlamingo-01: Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapyHER2/Neu +  Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based TherapyCT064
8Patritumab deruxtecanDaiichi SankyoHERTHENA-Lung02: A randomized Phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third generation EGFR tyrosine 
kinase inhibitor		Metastatic or Locally Advanced EGFRm NSCLC after failure of EGFR Tyrosine Kinase Inhibitor therapy (2L+)CT066
9Encorafenib + binimetinib + pembrolizumabPfizerSTARBOARD: Phase III study evaluating encorafenib + binimetinib + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanomaUnresectable Locally Advanced or Metastatic BRAF V600-mutant Melanoma (1L)CT069
Phase III Abstracts presenting at AACR 2023
  1. Drawing attention to the Phase II data readout, we have cancer vaccine players Moderna and Transgene excited about their personalized therapy. Merck is readily evaluating its flagship product as a combination in high-grade serous ovarian carcinoma, Aadi Biosciences heading towards grabbing a tumor agnostic label in TSC1 or TSC2 mutation. We also await for Pieris and Hutchmed’s data in Gastric cancer, along with Affimed’s shift in focus by launching a combination of AFM13 with allogeneic NK cells in peripheral T-cell lymphoma.
S.NoDrugCompanyTitlePatient segmentAbstract
1mRNA-4157 + pembrolizumabModerna/Merck & CoKeynote-942 : A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from open-label Phase II mRNA-4157-P201High-Risk Melanoma (adjuvant)CT001
2AFM13AffimedREDIRECT: A Phase II study of AFM13 in patients with CD30-positive relapsed or refractory PTCLRelapsed or Refractory CD30-positive PTCL (2L)CT024
3TG4001 + avelumabTransgenePhase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) HPV-16 positive anogenital cancersPatients With HPV-16 Positive Recurrent or Metastatic Malignancies (2L)CT045
4Pembrolizumab + Standard of Care (SOC) ± MK-4830Merck  & CoMK-4830-002: Phase II study of pembrolizumab + chemotherapy ± MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancerNeoadjuvant Treatment for High-Grade Serous Ovarian CancerCT046
5JDQ443Novartis PharmaceuticalsA Phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutationLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation (1L)CT048
6Nab-sirolimusAadi BiosciencePRECISION I: Phase II, multicenter open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 GenesCT057
7SavolitinibHutchmedPhase II study of savolitinib in patients with METamplified gastroesophogeal junctio (GE) n adenocarcinomas or gastric cancerGastric Cancer and Esophagogastric Junction Adenocarcinoma Patients With MET Gene Amplifications (2L)CT152
8Cinrebafusp alfa + ramucirumab + paclitaxelPieris PharmaceuticalsCombination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in patients with HER2-positive gastric /GEJ adenocarcinoma in Phase IIHER2+ Gastric or GEJ Adenocarcinoma (3L)CT154
9Tisotumab vedotinSeageninnovaTV 207: Tisotumab vedotin in squamous cell carcinoma of head and neck (SCCHN): interim analysis from Phase IISquamous cell carcinoma of head and neck CT164
10Telisotuzumab vedotinAbbVieLUMINOSITY: Preliminary efficacy of telisotuzumab vedotin treatment in the 2L/3L setting in MET gene amplified (MET Amp), c-Met protein overexpressing (c-Met OE), non-squamous NSCLCc-Met+ Non-Small Cell Lung Cancer (2L/3L)CT214
Phase II Abstracts Presenting at AACR 2023
  1. Post Amgen’s Lumakras and Mirati’s Krazati’s approval in targeting KRAS mutations, we have a huge list of contenders ready to enter the most lucrative KRASG12C space, including Eli Lilly, Genentech, and Genfleet, whereas MapKure, Kinnate and BeiGene focus on targeting the RAF pathway.
S.NoDrugCompanyTitlePatient segmentAbstract
1LY3537982Eli Lilly and CompanyA first-in-human Phase I study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12Cmutant advanced solid tumorsKRAS G12C-Mutant Advanced Solid TumorsCT028
2GDC-6036 + cetuximabGenentech/RochePhase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutationColorectal cancer with KRAS G12C mutationCT029
3IBI351 (GFH925)Genfleet TherapeuticsPhase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I studyAdvanced Solid Tumors With KRAS G12C MutationsCT030
4BGB-3245MapKureA first-in-human, Phase Ia/Ib, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumorsAdvanced or Refractory TumorsCT031
5Exarafenib (KIN-2787)Kinnate BiopharmaTrials in progress: a global Phase I/Ib clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanomaBRAF/NRAS-mutated advanced or Metastatic Solid tumorsCT032
6BGB-283 (lifirafenib) + PD-0325901 (mirdametinib)BeiGene/SpringWorks TherapeuticsSafety, pharmacokinetics, and antitumor activity findings from a Phase Ib, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumorsPatients With Advanced or Refractory Solid TumorsCT033
KRAS Pathway Abstracts Presenting at AACR 2023

S.NoDrugCompanyTitlePatient segmentAbstract
1Sacituzumab govitecan + zimberelimab + etrumadenantGilead SciencesVELOCITY-Lung: A phase II study evaluating safety and efficacy of sacituzumab govitecan + zimberelimab  + etrumadenant in patients with advanced or metastatic non-small cell lung cancer (mNSCLC) progressing on or after platinum (PT)- based chemotherapy and checkpoint inhibitors (CPI)Advanced or mNSCLC (1L)CT049
2Imvotamab + ZYNLONTA (loncastuximab tesirine)IGM BiosciencesA phase I/II randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomasRelapsed or Refractory B Cell NHL (3L+)CT052
3Datopotamab deruxtecan ±  Anticancer AgentsAstraZeneca/Daiichi SankyoTROPION-PanTumor03: Phase II, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients  with advanced/metastatic solid tumorsAdvanced or Metastatic Solid TumoursCT058
4Pembrolizumab ± sacituzumab govitecanMerck & Co/Gilead SciencesPembrolizumab with and without sacituzumab govitecan as first line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS ≥50%: phase III KEYNOTE-D46/EVOKE-03 studyParticipants With PD L1 TPS Greater Than or Equal to ≥50% mNSCLC (1L)CT067
5AL102Ayala PharmaceuticalsDouble-blind placebo-controlled trial of AL102 for treatment of progressing desmoid tumors: the RINGSIDE phase III study designPatients With Progressing Desmoid Tumors (1L+ , 2L+)CT070
Trial Design Abstracts Presenting in AACR 2023